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doi:10.1016/j.jmii.2011.01.035Background: Few studies focus on comparison of antimicrobial susceptibility for bacteremic
isolates in neutropenic and nonneutropenic cancer patients. The purpose of this study was
to elucidate the antimicrobial susceptibility of bacteremic isolates from cancer patients.
Methods: We collected bacterial isolates causing bloodstream infections in cancer patients at
a tertiary care hospital from 2003 to 2005 and performed in vitro antimicrobial susceptibility of
these pathogens by the disc diffusion method.
Results: A total of 588 bacterial isolates were identified from 476 episodes of bloodstream
infections in cancer patients. Major pathogens were Escherichia coli (22.4%), Klebsiella pneu-
moniae (17.6%), and Pseudomonas aeruginosa (14.1%) in neutropenic patients and E coli
(13.3%), K pneumoniae (10.1%), and Staphylococcus aureus (9.7%) in nonneutropenic patients.
Of S aureus, 55.8% were resistant to methicillin, and of coagulase-negative Staphylococcus
87.0%. Cefepime, cefpirome, piperacillin/tazobactam, meropenem, or imipenem in combina-
tion with or without an aminoglycoside, were active against more than 85% of gram-negative
bacilli (GNB). Ceftazidime, piperacillin, or ciprofloxacin plus an aminoglycoside were also
active against more than 85% of GNB. The susceptibility rate of GNB or gram-positive cocci
to any agent was not different between the isolates from neutropenic and nonneutropenic
patients, but more GNB isolates from the former were susceptible to imipenem or meropenem
plus an aminoglycoside.of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
u.edu.tw (W.-C. Ko).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Antimicrobial susceptibility of bacteremic isolates from cancer patients 377Conclusion: GNB remained dominant among bacteremic isolates in cancer patients. Antimicro-
bial agents, especially aminoglycoside-containing combination regimens, as recommended by
Infectious Diseases Society of Taiwan for febrile neutropenia, were active against more than
85% of GNB isolates.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Infection is the most common complication associated with
febrile neutropenia and accounts for substantial length of
stay, cost, morbidity, and mortality.1e3 The principles
guiding empirical antimicrobial therapy for patients with
febrile neutropenia are based on species distribution and
antimicrobial susceptibility of bacterial pathogens.
Although bacteria causing bloodstream infections (BSIs) in
cancer patients have not been uncommonly reported, little
is known about difference in antibiotic susceptibilities in
bacterial pathogens in cancer patients with and without
neutropenia.4e6 The availability of timely and accurate
epidemiological information on causative pathogens is
essential to the appropriate selection of empirical
therapy.7,8 This study was intended to understand bacte-
rial pathogens that caused BSIs in cancer patients with or
without neutropenia admitted between 2003 and 2005 at
a medical center in Taiwan and to investigate the suscep-
tibility profiles of these pathogens to antimicrobial agents
recommended by the Infectious Diseases Society of
Taiwan.9 Such information may be useful for clinicians at
starting empirical antimicrobial therapy for febrile cancer
patients.
Materials and methods
Setting and source of data
There were approximately 900 beds, including 100 beds
for cancer patients and 4 beds for bone marrow trans-
plantation in National Cheng Kung University Hospital,
a university-affiliated medical center in southern Taiwan.
We collected consecutive bacteremic isolates from adults
(agedS18 years) with cancer during study period. In cases
of recurrent bacteremia caused by the same pathogen,
only the isolates obtained from the first episode were
included. Each set of blood culture consisted of two
bottles, one for Standard Aerobic/F bottle and the other
for Standard Anaerobic/F culture. The substitute Plus
Aerobic/F and Anaerobic/F bottles were used if patients
had received antibiotics. At least two sets of blood
cultures were used, in which one contained at least
8e10 mL of blood collected from different vascular sites
at 30 minutes apart. Common blood culture contaminant
pathogens, such as coagulase-negative Staphylococcus,
Propionibacterium sp, or undifferentiated aerobic Gram-
positive bacilli, were excluded, unless they were isolated
from at least two sets of blood cultures. These bacteremic
isolates were stored at 70C until tested for
susceptibility.Definition
Neutropenia was defined as an absolute neutrophil count
equal to or less than 500 cells/mm3 in peripheral blood.
Episodes of polymicrobial bacteremia were those in which
more than one organism was isolated from one or more
blood cultures within a 72-hour period. Bacteremia was
considered to be nosocomial, if it was present beyond 48
hour after admission, without evidence of infection at
admission. Hematological malignancies included acute
myeloid leukemia, acute lymphoblastic leukemia, non-
Hodgkin’s lymphoma, multiple myeloma, chronic myeloid
leukemia, chronic lymphocytic leukemia, myelodysplastic
syndrome, aplastic anemia, and others.
Microbiological studies and antimicrobial
susceptibility
These blood cultureswere incubated at BACTEC 9240 system
(Becton Dickinson, Sparks, MD, USA) with tryptic soy agar
with 5% sheep blood, eosin-methylene blue agar, Chocolate
agar for aerobic, and CDC anaerobic blood agars for anaer-
obic cultures. All isolates were identified by standard
methods and the VITEK or API identification system (bio-
Me´rieux, Marcy l’Etoile, France).10,11 Antimicrobial suscep-
tibility was determined by the disk diffusionmethod and the
interpretive criteria of the Clinical and Laboratory Stan-
dards Institute11 were followed. Not all causative pathogens
and drugs had corresponding interpretive criteria recom-
mended by the Clinical and Laboratory Standards Institute.
Some modified strategies were adopted for such settings.
Like tigecycline, Food andDrug Administration disk diffusion
interpretive criteria are proposed for all strains.12,13 For
cefpirome, the breakpoints ofS18 mm as being susceptible
and &14 mm as being resistant were used.14,15 The disk
diffusion interpretive criteria in antibiotic susceptibility
tests of Gram-negative bacilli (GNB) other than themembers
of Enterobacteriaceae were used for rarely encountered
pathogens, such as Actinobacilius species, Alcaligenes
xylosoxidans, Brevundimonas vescularis,Chryseobacterium
species, Kluyvera species, Pantoea agglomerans, Pasteur-
ella multocida, and Stenotrophomonas maltophilia.
Antimicrobial agents for susceptibility tests (BD BBL
Sensi-Disc, Sparks, MD, USA) in aerobic gram-positive
organisms included vancomycin (30 mg), teicoplanin (30 mg),
linezolid (30 mg), tigecycline (15 mg), ceftazidime (30 mg),
cefepime (30 mg), cefpirome (30 mg), meropenem (10 mg),
imipenem (10 mg), ciprofloxacin (5 mg), piperacillin (100 mg),
piperacillin/tazobactam (100/10 mg), and gentamicin
(10 mg). Oxacillin (1 mg) was tested on Staphylococcus
species, and penicillin (10 mg) for Streptococcus species.
Table 1 The species distribution of bacteremic isolates
from cancer patients with or without neutropenia
Bacteria Isolate n (%) p
With
neutropenia
Without
neutropenia
Escherichia coli 76 (22.4) 33 (13.3) 0.005
Klebsiella pneumoniae 60 (17.6) 25 (10.1) 0.009
Pseudomonas aeruginosa 48 (14.1) 20 (8.1) 0.022
Enterobacter cloacae 25 (7.4) 18 (7.3) 0.971
Staphylococcus speciesa 23 (6.8) 23 (9.3) 0.263
Staphylococcus aureus 19 (5.6) 24 (9.7) 0.064
Enterococcus species 17 (5.0) 18 (7.3) 0.261
Streptococcus species 15 (4.4) 12 (4.8) 0.804
Acinetobacter speciesb 13 (3.8) 14 (5.6) 0.306
Acinetobacter baumannii 10 (2.9) 23 (9.3) 0.001
Pseudomonas speciesc 5 (1.5) 1 (0.4) 0.236
Klebsiella oxytoca 4 (1.2) 2 (0.8) 0.698
Others 25 (7.3) 35 (14.1)
Total 340 (100) 248 (100)
a Coagulase-negative Staphylococcus.
b Acinetobacter species other than Acinetobacter baumannii.
c Pseudomonas species other than Pseudomonas aeruginosa.
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negative organisms included tigecycline, ceftazidime,
cefepime, cefpirome, meropenem, imipenem, cipro-
floxacin, piperacillin, piperacillin/tazobactam, gentamicin,
and amikacin (30 mg). Minimal inhibitory concentration of
vancomycin for Enterococcus sp was performed by E-test
method in isolates with reduced susceptibility to
vancomycin.
Statistics
All statistical analyses were performed by the SPSS software
version 13.0 for Windows (SPSS Inc., Chicago, IL, USA).
Continuous variables were compared by Student t test,
whereas categorical variables were compared by c2 test or
two-tailed Fisher’s exact test. A p values less than 0.05 were
considered to be statistically significant.
Results
During the study period, 588 isolates from 476 episodes of
BSIs were collected. Of 476 episodes of BSIs, 275 occurred in
patients with neutropenia and 201 in patients without neu-
tropenia. There were 77 (22.6%) Gram-positive cocci (GPC)
isolates and 263 (77.4%) GNB isolates obtained from neu-
tropenic cancer patients, and 76 (30.6%) GPC and 172
(69.4%) GNB recovered from those without neutropenia. The
proportions of GNB of bacteremic isolates were 73.5% in
2003, 69.7% in 2004, and 72.9% in 2005, respectively. There
were 82 episodes of polymicrobial bacteremia, that is, 50
episodes in neutropenic patients and 32 in patients without
neutropenia. Of 275 neutropenic patients, 62.9% had
hematological malignancies; and of 201 nonneutropenic
patients, only 34.3% had hematological malignancies.
The distribution of causative microorganisms classified
according to neutropenia status among cancer patients was
listed in Table 1. Among neutropenic patients with BSIs,
Escherichia coli (22.4%), Klebsiella pneumoniae (17.6%), and
Pseudomonas aeruginosa (14.1%) were the most common
pathogens, more predominantly in neutropenic patients than
nonneutropenic patients. The three leading bacteremic
isolates in nonneutropenic groups were E coli (13.3%), K
pneumoniae (10.1%), and S aureus (9.7%). OnlyAcinetobacter
baumannii was more often recovered from nonneutropenic
patients. The percentage of Enterobacteriaceae in neu-
tropenic patients was higher than that in patients without
neutropenia (51.4% vs. 38.7%; pZ 0.002). Nosocomial path-
ogens were 411 bacteremic isolates. Three major nosocomial
pathogens were the same in patients with or without neu-
tropenia, that is, E coli, K pneumoniae, and P aeruginosa. The
fourth and fifth nosocomial pathogens were S aureus and
Enterobacter cloacae, and the ranking was in reverse order in
community-onset bacteremia.
There is no difference in the prevalence of GPC
bacteremia between cancer patients with or without neu-
tropenia. S aureus bacteremia comprised 5.6% and 9.7% of
all bacteremic isolates from patients with and without
neutropenia, respectively. Of total 43 S aureus isolates,
methicillin-resistant S aureus accounted for 55.8%. Methi-
cillin resistance was found in 87.0% of 46 coagulase-nega-
tive Staphylococcus isolates and ampicillin resistance in45.5% of 35 Enterococcus isolates. Only one Enterococcus
faecalis isolate displayed a reduced susceptibility to van-
comycin (minimal inhibitory concentrationZ 16 mg/mL)
during this study period.
Antimicrobial susceptibility of monotherapy for bacter-
emic isolates from neutropenic cancer patients and those
without neutropenia were not different. The ceftazidime,
cefepime, cefpirome, piperacillin/tazobactam, mer-
openem, imipenem, and amikacin were in vitro active
against more than 80% of GNB (Table 2). Of GPC, tigecy-
cline, linezolid, teicoplanin, and vancomycin were active
against more than 90% (Table 3).
Antimicrobial susceptibility of commonly prescribed
antibiotics in combination with gentamicin or amikacin for
cancer patients with or without neutropenia was listed in
Table 4. Most antibiotics, except pipracillin, in combination
with gentamicin in Table 4 were in vitro active against more
than 85% GNB from cancer patients. In combination with
amikacin, all drugs were in vitro active against more than
90% GNB from cancer patients regardless of neutrophil
counts, as shown in Table 4. Imipenem or meropenem plus
an aminoglycoside were more active for GNB isolates from
cancer patients with neutropenia than those with non-
neutropenia: gentamicin-containing regimens: 98.5% versus
94.8% (pZ 0.03) and amikacin-containing regimens: 99.2%
versus 95.3% (pZ 0.01).
Discussion
How to choose appropriate antibiotics with less cost, less
toxicity, little collateral damage, and more effective anti-
microbial agents for sepsis in oncologic patients is always an
important issue and a great challenge. Our study focuses on
antimicrobial susceptibility in BSIs in bacteremic isolates
from cancer patients with or without neutropenia. These
Table 2 Antimicrobial susceptibility of Gram-negative bacilli from bloodstream of cancer patients with or without
neutropenia
Drugs Susceptible rate, % p
Isolates from patients with
neutropenia, nZ 263
Isolates from patients
without neutropenia, nZ 172
Tigecycline 78.3 82.0 0.36
Ciprofloxacin 81.7 78.4 0.40
Ceftazidime 84.4 86.0 0.65
Cefepime 91.2 91.2 1
Cefpirome 85.2 85.4 0.94
Meropenem 97.0 93.6 0.11
Imipenem 96.6 93.6 0.16
Piperacillin 50.6 50.6 1
Piperacillin/tazobactam 86.3 87.8 0.66
Gentamicin 78.3 71.5 0.11
Amikacin 93.5 89.5 0.14
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otics in patient care. The predominant etiology of BSIs in
cancer patients with neutropenia has been reported to be
gram-positive organisms in recent studies.16e18 However,
previous studies in Taiwan 6,19 and our data showed that GNB
remain being responsible for most causative microorganisms
of BSIs in cancer patients who were neutropenic or not.
A high prevalence of Enterobacteriaceae bacteremia in
neutropenic cancer patients with BSIs, at least 51.4%, may
be explained by breaking down of gastrointestinal mucosal
barrier. However, the prevalence of Pseudomonas aerugi-
nosa bacteremia in neutropenic patients was 14.1%, twice
that in nonneutropenic cancer patients. Such a causative
species discrepancy highlights the precaution in choosing
empirical antibiotics for cancer patients with and without
neutropenia.
As the study by Velasco et al.,4 antimicrobial suscepti-
bility of bacteremic isolates among GNB and GPC isolatesTable 3 Antimicrobial susceptibility of Gram-positive cocci from
Drugs Su
Isolates from patients
with neutropenia, nZ 77
Tigecycline 96.1
Teicoplanin 100
Vancomycina 97.4
Linezolid 96.1
Ciprofloxacin 37.7
Ceftazidime 31.1
Cefepime 49.4
Cefpirome 45.4
Meropenem 53.2
Imipenem 63.6
Piperacillin 44.2
Piperacillin/tazobactam 70.1
Gentamicin 36.4
a The susceptible breakpoint of vancomycin using disk diffusion te
deleted the susceptible disk diffusion breakpoint of vancomycin for s
CLSIZ Clinical and Laboratory Standards Institute.from our cancer patients with and without neutropenia was
not different. Substantial percentages of methicillin and
ampicillin resistance were present in our Staphylococcus
and Enterococcus isolates, respectively, either in neu-
tropenic or nonneutropenic patients. It reminds us to pay
attention to risky patients for GPC infections and the needs
of glycopeptides, tigecycline, or linezolid for b-lactam-
resistant gram-positive pathogens. Tigecycline, although in
vitro active against GPC isolates, low serum concentrations
of tigecycline will probably limit its therapeutic efficacy in
treating BSIs. However, a recent meta-analysis revealed no
benefit for the role of glycopeptides in the initial empirical
treatment of febrile neutropenic cases, and the adverse
effects, including nephrotoxicity, were higher in the group
of empirical vancomycin treatment.20 Further study is
needed to determine the optimal choices and timing of
empirical antibiotic use for b-lactam-resistant Gram-posi-
tive pathogens.bloodstream of cancer patients with or without neutropenia
sceptible rate, % p
Isolates from patients
without neutropenia, nZ 76
98.7 0.38
100 1
97.3 0.99
97.4 0.69
40.8 0.70
25.0 0.40
40.8 0.29
36.8 0.29
46.1 0.38
60.5 0.70
38.2 0.46
63.2 0.37
26.3 0.19
st was recommended by 2005 CLSI. However, in 2009, the CLSI
taphylococci because of unreliable differentiation.
Table 4 Susceptibility rates of Gram-negative bacillary bacteremic isolates from cancer patients with or without neutropenia
to gentamicin-based/amikacin-based combination regimens
Combination regimens Susceptible rate, % p
Neutropenic nZ 263 Nonneutropenic nZ 172
Ceftazidimeþ gentamicin 92.0 89.0 0.29
Cefepimeþ gentamicin 95.4 92.4 0.20
Cefpiromeþ gentamicin 92.0 90.1 0.49
Meropenemþ gentamicin 98.5 94.8 0.03
Imipenemþ gentamicin 98.5 94.8 0.03
Piperacillinþ gentamicin 81.0 78.0 0.44
Piperacillin/
tazobactamþ gentamicin
94.3 91.9 0.33
Ciprofloxacinþ gentamicin 89.0 86.6 0.46
Ceftazidimeþ amikacin 95.4 93.6 0.41
Cefepimeþ amikacin 96.6 93.6 0.16
Cefpiromeþ amikacin 95.8 92.4 0.14
Meropenemþ amikacin 99.2 95.3 0.01
Imipenemþ amikacin 99.2 95.3 0.01
Ciprofloxacinþ amikacin 97.7 94.8 0.11
Piperacillinþ amikacin 95.1 93.0 0.38
Piperacillin/
tazobactamþ amikacin
97.3 97.1 0.87
Note: The effects of two antibiotics in combination were calculated as the concurrent susceptibilities against either of two drugs.
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tious Diseases Society of Taiwan for patients with febrile
neutropenia, including cefepime, a carbapenem, cefe-
pime, or cefpirome plus gentamicin or amikacin, ceftazi-
dime plus amikacin, a carbapenem plus gentamicin or
amikacin, piperacillin/tazobactam plus gentamicin or
amikacin,9 were in vitro active against more than 90% of
GNB causing BSIs in our cancer patients, irrespective of
neutropenic status. The in vitro susceptibility data sup-
ported that these regimens can be appropriate choices in
empirical use for febrile neutropenia in Taiwan. In a study
by Sunil et al.,21 routine combination of amikacin and a b-
lactam agent can increase the adequacy of empirical
coverage. For GNB sepsis, piperacillin or ciprofloxacin in
combination with an aminoglycoside, especially amikacin,
showed better in vitro antibacterial activity. Ciprofloxacin
combined with an aminoglycoside can be considered when
facing patients with febrile neutropenia and b-lactam
allergy history.
In recent meta-analysis studies, monotherapy has been
proved as effective as aminoglycoside-containing combi-
nations for empirical treatment of febrile neutropenia.22,23
The advantage of monotherapy included easier to adminis-
tering, possibly cheaper than combination therapy, and low
toxicity, especially nephrotoxicity. However, the mortality
rate of P aeruginosa bacteremiawould be significantly lower
in patients treated by combination therapy or initial
combination therapy followed by an adequate definitive
monotherapy.24,25 Combination therapy, including a fluo-
roquinolone either with an antipseudomonal b-lactam or
amikacin, or an antipseudomonal b-lactam with an amino-
glycoside, could in vitro minimize the risk of developing
resistance.26,27 In our study, P aeruginosa ranked the third in
neutropenic patients and the sixth in nonneutropenic
patients. It was reasonable to take combination strategy asan alternative choice in empirical therapy in febrile cancer
patients with or without neutropenia.
Our study has at least three major limitations. The first is
the samples collected from a single medical center; such
results may be not bale to be generalized to other medical
centers in Taiwan. The second limitation is the combination
of two drugs. We did not evaluate the in vitro antibacterial
effect of two drugs in combination but just simply counted
the susceptibility data of causative pathogens to either of
two antibiotics. The last limitation is the changing inter-
pretative criteria of disk diffusion tests to certain patho-
gens, such as the vancomycin disk for methicillin-resistant S
aureus or carbapenem disks for Enterobacteriacea. It
highlights the need of frequent updating of such suscepti-
bility profiles.
In conclusion, our data show GNB were the dominant
organisms causing BSIs. Antimicrobial susceptibility data
supported the recommended antimicrobial agents in febrile
neutropenic patients by the Infectious Diseases Society of
Taiwan. When GPC infections are suspected, a glycopeptide
can be considered with the concern of b-lactam resistance.
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